# Evaluation of Perilesional Biopsy in Diagnosis of Prostate Cancer

> **NCT06482645** · NA · RECRUITING · sponsor: **Peking University First Hospital** · enrollment: 300 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **PROCEDURE:** Perilesional/regional systematic biopsy
- **PROCEDURE:** Combination of systematic biopsy and targeted biopsy

## Key facts

- **NCT ID:** NCT06482645
- **Lead sponsor:** Peking University First Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2025-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2024-07-23

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06482645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06482645, "Evaluation of Perilesional Biopsy in Diagnosis of Prostate Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06482645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*